254 related articles for article (PubMed ID: 38673838)
21. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
22. ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients.
Glazewska EK; Niczyporuk M; Lawicki S; Szmitkowski M; Zajkowska M; Donejko M; Przylipiak A
Postepy Dermatol Alergol; 2018 Apr; 35(2):167-173. PubMed ID: 29760617
[TBL] [Abstract][Full Text] [Related]
23. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract][Full Text] [Related]
24. Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19-9 and CEA.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Pol Arch Intern Med; 2018 Sep; 128(9):524-531. PubMed ID: 30057378
[TBL] [Abstract][Full Text] [Related]
25. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio.
Wei XL; Wang FH; Zhang DS; Qiu MZ; Ren C; Jin Y; Zhou YX; Wang DS; He MM; Bai L; Wang F; Luo HY; Li YH; Xu RH
BMC Cancer; 2015 May; 15():350. PubMed ID: 25934640
[TBL] [Abstract][Full Text] [Related]
26. Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer.
Pawluczuk E; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680333
[TBL] [Abstract][Full Text] [Related]
27. ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma.
Liu L; Yang Z; Ni W; Xuan Y
Exp Mol Pathol; 2018 Apr; 104(2):134-139. PubMed ID: 29475036
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma.
Bister V; Skoog T; Virolainen S; Kiviluoto T; Puolakkainen P; Saarialho-Kere U
Mod Pathol; 2007 Nov; 20(11):1128-40. PubMed ID: 17873896
[TBL] [Abstract][Full Text] [Related]
29. Increased MMP-21 expression in esophageal squamous cell carcinoma is associated with progression and prognosis.
Zhao Z; Yan L; Li S; Sun H; Zhou Y; Li X
Med Oncol; 2014 Aug; 31(8):91. PubMed ID: 25015395
[TBL] [Abstract][Full Text] [Related]
30. Increase in serum platelet-derived growth factor (PDGF)-BB reflects lymph node involvement in esophageal cancer patients independently from platelet count.
Krzystek-Korpacka M; Diakowska D; Gamian A; Matusiewicz M
Exp Oncol; 2011 Sep; 33(3):140-4. PubMed ID: 21956466
[TBL] [Abstract][Full Text] [Related]
31. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma.
Gotoda T; Matsumura Y; Kondo H; Ono H; Kanamoto A; Kato H; Watanabe H; Tachimori Y; Nakanishi Y; Kakizoe T
Gut; 2000 Jan; 46(1):14-9. PubMed ID: 10601048
[TBL] [Abstract][Full Text] [Related]
32. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.
Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS
Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract][Full Text] [Related]
34. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.
Mroczko B; Groblewska M; Okulczyk B; Kedra B; Szmitkowski M
Int J Colorectal Dis; 2010 Oct; 25(10):1177-84. PubMed ID: 20556397
[TBL] [Abstract][Full Text] [Related]
35. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
36. The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases -2 and -9 in lymph node-negative untreated breast cancer patients.
Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
J BUON; 2013; 18(4):866-73. PubMed ID: 24344010
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
38. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
39. Rat tail static compression model mimics extracellular matrix metabolic imbalances of matrix metalloproteinases, aggrecanases, and tissue inhibitors of metalloproteinases in intervertebral disc degeneration.
Yurube T; Takada T; Suzuki T; Kakutani K; Maeno K; Doita M; Kurosaka M; Nishida K
Arthritis Res Ther; 2012 Mar; 14(2):R51. PubMed ID: 22394620
[TBL] [Abstract][Full Text] [Related]
40. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer.
Sato F; Shimada Y; Watanabe G; Uchida S; Makino T; Imamura M
Br J Cancer; 1999 Jul; 80(9):1366-72. PubMed ID: 10424737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
